

## **Pneumococcal Vaccine Market Report and Forecast 2024-2032**

Market Report | 2023-10-01 | 160 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$2999.00
- Five User License \$3999.00
- Corporate License \$5999.00

### **Report description:**

Global Pneumococcal Vaccine Market Report and Forecast 2024-2032

#### Global Pneumococcal Vaccine Market Outlook

The global pneumococcal vaccine market size was valued at USD 8.61 million in 2023, driven by the heightened recognition of the importance of preventive measures against pneumococcal diseases, which can lead to conditions such as pneumonia, meningitis, and sepsis across the globe. The market size is anticipated to grow at a CAGR of 4.9% during the forecast period of 2024-2032 to achieve a value of USD 13.21 million by 2032.

#### Pneumococcal Vaccine: Introduction

Pneumococcal vaccines are vital tools in the prevention of diseases caused by the *Streptococcus pneumoniae* bacteria. This bacterium can lead to a range of serious conditions, including pneumonia, meningitis, and bloodstream infections, particularly in young children, the elderly, and individuals with compromised immune systems. The pneumococcal vaccines stimulate the immune system to produce antibodies against specific serotypes or strains of the bacteria, offering protection against subsequent infections.

There are two primary types of pneumococcal vaccines: the pneumococcal conjugate vaccine (PCV) and the pneumococcal polysaccharide vaccine (PPSV). Each targets different serotypes and is recommended based on age and health conditions. The widespread use of these vaccines has significantly reduced the incidence of pneumococcal diseases in many parts of the world, showcasing their importance in public health initiatives.

#### Key Trends in the Global Pneumococcal Vaccine Market

The global pneumococcal vaccine market is witnessing several dynamic trends that reflect the global commitment to combat pneumococcal diseases. Firstly, there is an increased emphasis on expanding vaccination coverage, especially in low and

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

middle-income countries, propelled by global health organizations and initiatives like Gavi, the Vaccine Alliance. There's also a notable shift towards the development of broader-spectrum vaccines, aiming to cover a wider range of pneumococcal serotypes prevalent in different regions. Research and development in the vaccine space are surging, with companies aiming to enhance vaccine efficacy, stability, and distribution methods. Another critical trend is the growing awareness campaigns and government-driven immunization programs, emphasizing the importance of pneumococcal vaccination across all age groups, especially in children and the elderly.

Additionally, public-private partnerships are facilitating quicker development, production, and distribution of vaccines, ensuring broader access. With the rising global focus on preventive healthcare and the challenges posed by evolving bacterial strains, the pneumococcal vaccine market is set to experience sustained growth and diversification.

#### Global Pneumococcal Vaccine Market Segmentation

##### Market Breakup by Vaccine Type

- Conjugate Vaccine
- Polysaccharide Vaccine

##### Market Breakup by Product Type

- Pevnar 13
- Synflorix
- neumovax23

##### Market Breakup by Distribution Channel

- Distribution Partner Companies
- Non-Governmental Organizations
- Government Authorities

##### Market Breakup by Region

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

#### Global Pneumococcal Vaccine Market Overview

The global pneumococcal vaccine market plays a pivotal role in the broader immunization landscape, given the severity of diseases caused by the *Streptococcus pneumoniae* bacteria. This market has witnessed robust growth, driven by the heightened recognition of the importance of preventive measures against pneumococcal diseases, which can lead to conditions such as pneumonia, meningitis, and sepsis. The demand for both primary types of pneumococcal vaccines, namely the pneumococcal conjugate vaccine (PCV) and the pneumococcal polysaccharide vaccine (PPSV), remains substantial, catering to different age groups and health demographics.

While developed regions like North America and Europe have seen extensive vaccine coverage, concerted efforts are underway to expand immunization in low and middle-income countries. Collaborative initiatives, involving global health bodies and organizations like Gavi, have been instrumental in facilitating this expansion. With evolving bacterial serotypes, the push for broader-spectrum vaccines is gaining momentum, leading to increased research and development activities. As global health

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

priorities continue to emphasize preventive measures and improved access to vaccines, the pneumococcal vaccine market is poised for continued growth and expansion in the coming years.

#### Global Pneumococcal Vaccine Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- GlaxoSmithKline, Plc.
- Sanofi
- Merck & Co.
- Panacea Biotech
- Pfizer Inc
- PnuVax Incorporated
- SK bioscience
- Walvax Biotechnology Co.
- Beijing Minhai Biotechnology Co.
- Serum Institute of India

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

#### Table of Contents:

- 1 Preface
  - 1.1 Objectives of the Study
  - 1.2 Key Assumptions
  - 1.3 Report Coverage - Key Segmentation and Scope
  - 1.4 Research Methodology
- 2 Executive Summary
- 3 Pneumococcal Disease Overview
  - 3.1 Guidelines and Stages
  - 3.2 Pathophysiology
  - 3.3 Screening and Diagnosis
  - 3.4 Treatment Pathway
- 4 Patient Profile
  - 4.1 Patient Profile Overview
  - 4.2 Patient Psychology and Emotional Impact Factors
  - 4.3 Risk Assessment and Treatment Success Rate
- 5 Pneumococcal Disease Epidemiology Analysis - 7MM
  - 5.1 7MM Epidemiology Scenario Overview (2017-2032)
  - 5.2 United States Pneumococcal Disease Epidemiology Forecast (2017-2032)
  - 5.3 EU-4 and United Kingdom Pneumococcal Disease Epidemiology Forecast (2017-2032)
    - 5.3.1 Germany Pneumococcal Disease Epidemiology Forecast (2017-2032)
    - 5.3.2 France Pneumococcal Disease Epidemiology Forecast (2017-2032)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 5.3.3 Italy Pneumococcal Disease Epidemiology Forecast (2017-2032)
- 5.3.4 Spain Pneumococcal Disease Epidemiology Forecast (2017-2032)
- 5.3.5 United Kingdom Pneumococcal Disease Epidemiology Forecast (2017-2032)
- 5.4 Japan Pneumococcal Disease Epidemiology Forecast (2017-2032)
- 6 Pneumococcal Vaccine Market Overview - 7MM
  - 6.1 Pneumococcal Vaccine Market Historical Value (2017-2023)
  - 6.2 Pneumococcal Vaccine Market Forecast Value (2024-2032)
- 7 Pneumococcal Vaccine Market Landscape - 7MM
  - 7.1 Pneumococcal Vaccine: Developers Landscape
    - 7.1.1 Analysis by Year of Establishment
    - 7.1.2 Analysis by Company Size
    - 7.1.3 Analysis by Region
  - 7.2 Pneumococcal Vaccine Product Landscape
    - 7.2.1 Analysis by Vaccine Type
    - 7.2.2 Analysis by Product Type
- 8 Pneumococcal Vaccine Challenges and Unmet Needs
  - 8.1 Treatment Pathway Challenges
  - 8.2 Compliance and Drop-Out Analysis
  - 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Pneumococcal Vaccine Market Dynamics
  - 10.1 Market Drivers and Constraints
  - 10.2 SWOT Analysis
  - 10.3 Porter's Five Forces Model
  - 10.4 Key Demand Indicators
  - 10.5 Key Price Indicators
  - 10.6 Industry Events, Initiatives, and Trends
  - 10.7 Value Chain Analysis
- 11 Pneumococcal Vaccine Market Segmentation - 7MM
  - 11.1 Pneumococcal Vaccine Market by Vaccine Type
    - 11.1.1 Market Overview
    - 11.1.2 Conjugate vaccine
    - 11.1.3 Polysaccharide vaccine
  - 11.2 Pneumococcal Vaccine Market by Product Type
    - 11.2.1 Market Overview
    - 11.2.2 Prevnar 13
    - 11.2.3 Synflorix
    - 11.2.4 neumovax23
  - 11.3 Pneumococcal Vaccine Market by Distribution Channel
    - 11.3.1 Market Overview
    - 11.3.2 Distribution partner companies
    - 11.3.3 Non-governmental Organizations
    - 11.3.4 Government Authorities
  - 11.4 Pneumococcal Vaccine Market by Region
    - 11.4.1 Market Overview
    - 11.4.2 United States
    - 11.4.3 EU-4 and the United Kingdom

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 11.4.3.1 Germany
- 11.4.3.2 France
- 11.4.3.3 Italy
- 11.4.3.4 Spain
- 11.4.3.5 United Kingdom
- 11.4.4 Japan
- 12 United States Pneumococcal Vaccine Market
  - 12.1 Pneumococcal Vaccine Market Historical Value (2017-2023)
  - 12.2 Pneumococcal Vaccine Market Forecast Value (2024-2032)
  - 12.3 Pneumococcal Vaccine Market by Vaccine Type
  - 12.4 Pneumococcal Vaccine Market by Product Type
- 13 EU-4 and United Kingdom Pneumococcal Vaccine Market
  - 13.1 Pneumococcal Vaccine Market Historical Value (2017-2023)
  - 13.2 Pneumococcal Vaccine Market Forecast Value (2024-2032)
  - 13.3 Germany Pneumococcal Vaccine Market Overview
    - 13.3.1 Pneumococcal Vaccine Market by Vaccine Type
    - 13.3.2 Pneumococcal Vaccine Market by Product Type
  - 13.4 France Pneumococcal Vaccine Market Overview
    - 13.4.1 Pneumococcal Vaccine Market by Vaccine Type
    - 13.4.2 Pneumococcal Vaccine Market by Product Type
  - 13.5 Italy Pneumococcal Vaccine Market Overview
    - 13.5.1 Pneumococcal Vaccine Market by Vaccine Type
    - 13.5.2 Pneumococcal Vaccine Market by Product Type
  - 13.6 Spain Pneumococcal Vaccine Market Overview
    - 13.6.1 Pneumococcal Vaccine Market by Vaccine Type
    - 13.6.2 Pneumococcal Vaccine Market by Product Type
  - 13.7 United Kingdom Pneumococcal Vaccine Market Overview
    - 13.7.1 Pneumococcal Vaccine Market by Vaccine Type
    - 13.7.2 Pneumococcal Vaccine Market by Product Type
- 14 Japan Pneumococcal Vaccine Market
  - 14.1 Pneumococcal Vaccine Market Historical Value (2017-2023)
  - 14.2 Pneumococcal Vaccine Market Forecast Value (2024-2032)
  - 14.3 Pneumococcal Vaccine Market by Vaccine Type
  - 14.4 Pneumococcal Vaccine Market by Product Type
- 15 Regulatory Framework
  - 15.1 Regulatory Overview
    - 15.1.1 US FDA
    - 15.1.2 EU EMA
    - 15.1.3 JAPAN PMDA
- 16 Patent Analysis
  - 16.1 Analysis by Type of Patent
  - 16.2 Analysis by Publication year
  - 16.3 Analysis by Issuing Authority
  - 16.4 Analysis by Patent Age
  - 16.5 Analysis by CPC Analysis
  - 16.6 Analysis by Patent Valuation
  - 16.7 Analysis by Key Players

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 17 Grants Analysis
  - 17.1 Analysis by year
  - 17.2 Analysis by Amount Awarded
  - 17.3 Analysis by Issuing Authority
  - 17.4 Analysis by Grant Application
  - 17.5 Analysis by Funding Institute
  - 17.6 Analysis by NIH Departments
  - 17.7 Analysis by Recipient Organization
- 18 Clinical Trials Analysis
  - 18.1 Analysis by Trial Registration Year
  - 18.2 Analysis by Trial Status
  - 18.3 Analysis by Trial Phase
  - 18.4 Analysis by Therapeutic Area
  - 18.5 Analysis by Geography
- 19 Funding and Investment Analysis
  - 19.1 Analysis by Funding Instances
  - 19.2 Analysis by Type of Funding
  - 19.3 Analysis by Funding Amount
  - 19.4 Analysis by Leading Players
  - 19.5 Analysis by Leading Investors
  - 19.6 Analysis by Geography
- 20 Partnerships and Collaborations Analysis
  - 20.1 Analysis by Partnership Instances
  - 20.2 Analysis by Type of Partnership
  - 20.3 Analysis by Leading Players
  - 20.4 Analysis by Geography
- 21 Supplier Landscape
  - 21.1 GlaxoSmithKline, Plc.
    - 21.1.1 Financial Analysis
    - 21.1.2 Product Portfolio
    - 21.1.3 Demographic Reach and Achievements
    - 21.1.4 Mergers and Acquisitions
    - 21.1.5 Certifications
  - 21.2 Sanofi
    - 21.2.1 Financial Analysis
    - 21.2.2 Product Portfolio
    - 21.2.3 Demographic Reach and Achievements
    - 21.2.4 Mergers and Acquisitions
    - 21.2.5 Certifications
  - 21.3 Merck & Co.
    - 21.3.1 Financial Analysis
    - 21.3.2 Product Portfolio
    - 21.3.3 Demographic Reach and Achievements
    - 21.3.4 Mergers and Acquisitions
    - 21.3.5 Certifications
  - 21.4 Panacea Biotech
    - 21.4.1 Financial Analysis

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 21.4.2 Product Portfolio
- 21.4.3 Demographic Reach and Achievements
- 21.4.4 Mergers and Acquisitions
- 21.4.5 Certifications
- 21.5 Pfizer Inc
  - 21.5.1 Financial Analysis
  - 21.5.2 Product Portfolio
  - 21.5.3 Demographic Reach and Achievements
  - 21.5.4 Mergers and Acquisitions
  - 21.5.5 Certifications
- 21.6 PnuVax Incorporated
  - 21.6.1 Financial Analysis
  - 21.6.2 Product Portfolio
  - 21.6.3 Demographic Reach and Achievements
  - 21.6.4 Mergers and Acquisitions
  - 21.6.5 Certifications
- 21.7 SK bioscience
  - 21.7.1 Financial Analysis
  - 21.7.2 Product Portfolio
  - 21.7.3 Demographic Reach and Achievements
  - 21.7.4 Mergers and Acquisitions
  - 21.7.5 Certifications
- 21.8 Walvax Biotechnology Co.
  - 21.8.1 Financial Analysis
  - 21.8.2 Product Portfolio
  - 21.8.3 Demographic Reach and Achievements
  - 21.8.4 Mergers and Acquisitions
  - 21.8.5 Certifications
- 21.9 Beijing Minhai Biotechnology Co.
  - 21.9.1 Financial Analysis
  - 21.9.2 Product Portfolio
  - 21.9.3 Demographic Reach and Achievements
  - 21.9.4 Mergers and Acquisitions
  - 21.9.5 Certifications
- 21.10 Serum Institute of India
  - 21.10.1 Financial Analysis
  - 21.10.2 Product Portfolio
  - 21.10.3 Demographic Reach and Achievements
  - 21.10.4 Mergers and Acquisitions
  - 21.10.5 Certifications
- 22 Pneumococcal Vaccine Market- Distribution Model (Additional Insight)
  - 22.1 Overview
  - 22.2 Potential Distributors
  - 22.3 Key Parameters for Distribution Partner Assessment
- 23 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 24 Company Competitiveness Analysis (Additional Insight)
  - 24.1 Very Small Companies

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 24.2 Small Companies
- 24.3 Mid-Sized Companies
- 24.4 Large Companies
- 24.5 Very Large Companies
- 25 Payment Methods (Additional Insight)
  - 25.1 Government Funded
  - 25.2 Private Insurance
  - 25.3 Out-of-Pocket

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Pneumococcal Vaccine Market Report and Forecast 2024-2032**

Market Report | 2023-10-01 | 160 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$2999.00
	Five User License	\$3999.00
	Corporate License	\$5999.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com